Company intelligence / Profile preview

SciSparc

Tel Aviv–Yafo, Tel Aviv District, Israelscisparc.com ↗
Ownership
Public · SPRC
Employees
~2
Development stage
Phase 2
01

Overview

SciSparc is a clinical-stage specialty pharmaceutical company developing proprietary cannabinoid-based therapies for central nervous system disorders. Its lead candidate, SCI‑110, is in Phase 2 trials for Tourette syndrome and Alzheimer’s-related agitation. Other programs target autism spectrum disorder, status epilepticus, chronic pain, and rare mitochondrial diseases. The company has demonstrated improved efficacy and safety profiles in early clinical studies[1][3][4].

Therapeutic areas
PulmonologyPsychiatryNeurology
Modalities
Small moleculeSynthetic cannabinoidCombination therapy (e.g., cannabinoids + N-acylethanolamines)
Industry
Biotech
02

Drug pipeline

3 assets

SCI-210

2

2 more assets in the full pipeline.

03

Partnerships

Procaps Group SAPolyrizon Ltd.Clearmind Medicine Inc.The Israeli Medical Center for Alzheimer’s
04

Financials

Market cap
$249.3K
Total revenue
$856K
Enterprise value
$-1.5M

Beyond the preview

Go deeper on SciSparc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciSparc.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call